Porcine reproductive and respiratory syndrome virus (PRRSV) an infection causes appreciable financial loss to the worldwide pig business. Environment friendly detection assay is essential for the prevention of the virus an infection. Nanobodies are some great benefits of small molecular weight, easy genetic engineering, and low manufacturing price for promising diagnostic software.
On this research, to develop a nanobody-based aggressive ELISA (cELISA) for particularly detecting antibodies towards PRRSV, three nanobodies towards PRRSV-N protein had been screened by Camel immunization, library building, and phage show. Subsequently, a recombinant HEK293S cell line stably secreting nanobody-horseradish peroxidase (HRP) fusion protein towards PRRSV-N protein was efficiently constructed utilizing the lentivirus transduction assay.
Utilizing the cell traces, the fusion protein was simply produced. Then, a novel cELISA was developed utilizing the nanobody-HRP fusion protein for detecting antibodies towards PRRSV in pig sera, exhibiting a cut-off worth of 23.19% and good sensitivity, specificity, and reproducibility. Importantly, the cELISA particularly detect anti-genotype 2 PRRSV antibodies.
The cELISA confirmed extra delicate than the business IDEXX ELISA equipment by detecting the sequential sera from the challenged pigs. The compliance charge of cELISA with the business IDEXX ELISA equipment was 96.4%. As well as, the business IDEXX ELISA equipment could be mixed with the developed cELISA for the differential detection of antibodies towards genotype 1 and a couple of PRRSV in pig sera. Collectively, the developed nanobody-based cELISA confirmed benefits of merely operation and low manufacturing price and could be as an assay for epidemiological investigation of genotype 2 PRRSV an infection in pigs and analysis after vaccination.
Saliva SARS-CoV-2 Antibody Prevalence in Kids
COVID-19 sufferers produce circulating and mucosal antibodies. In adults, particular saliva antibodies have been detected. Nonetheless, seroprevalence is routinely investigated, whereas little consideration has been paid to mucosal antibodies. We subsequently assessed SARS-CoV-2-specific antibody prevalence in serum and saliva in kids within the Netherlands. We assessed SARS-CoV-2 antibody prevalence in serum and saliva of 517 kids attending medical providers within the Netherlands (regardless of COVID-19 publicity) from April to October 2020.
The prevalence of SARS-CoV-2 spike (S), receptor binding area (RBD), and nucleocapsid (N)-specific IgG and IgA had been evaluated with an exploratory Luminex assay in serum and saliva and with the Wantai SARS-CoV-2 RBD complete antibody enzyme-linked immunosorbent assay in serum. Utilizing the Wantai assay, the RBD-specific antibody prevalence in serum was 3.3% (95% confidence interval [CI]. 1.9 to five.3%).
With the Luminex assay, we detected heterogeneity between antibodies for S, RBD, and N antigens, as IgG and IgA prevalence ranged between 3.6 and 4.6% in serum and between zero and 4.4% in saliva. The Luminex assay additionally revealed variations between serum and saliva, with SARS-CoV-2-specific IgG current in saliva however not in serum for 1.5 to 2.7% of all kids.
Utilizing a number of antigen assays, the IgG prevalence for a minimum of two out of three antigens (S, RBD, or N) in serum or saliva could be calculated as 3.8% (95% CI, 2.Three to five.6%). Our research shows the heterogeneity of the SARS-CoV-2 antibody response in kids and emphasizes the extra worth of saliva antibody detection and the mixed use of various antigens. IMPORTANCE Comprehending humoral immunity to SARS-CoV-2, together with in kids, is essential for future public well being and vaccine methods.
Others have prompt that mucosal antibody measurement may very well be an essential and extra handy instrument to judge humoral immunity in comparison with circulating antibodies. Nonetheless, seroprevalence is routinely investigated, whereas little consideration has been paid to mucosal antibodies. We present the heterogeneity of SARS-CoV-2 antibodies, when it comes to each antigen specificity and variations between circulating and mucosal antibodies, emphasizing the extra worth of saliva antibody detection subsequent to detection of antibodies in serum.
A aggressive hemagglutination inhibition assay for dissecting purposeful antibody exercise to influenza virus
Influenza stays one of the crucial contagious infectious illnesses. Roughly, 25-50 million individuals endure from influenza-like sickness in the USA yearly, resulting in virtually 1 million hospitalizations. Globally, the World Well being Group (WHO) estimates 250,000-500,000 mortalities related to secondary respiratory issues because of influenza virus an infection yearly. At present, seasonal vaccination represents one of the best countermeasure to stop influenza virus unfold and transmission within the basic inhabitants.
Nonetheless, presently licensed influenza vaccines are about 60% efficient on common, and their effectiveness varies from season to season and amongst age teams, in addition to between totally different influenza subtypes inside a single season. The hemagglutination inhibition (HAI) assay represents the gold commonplace technique for measuring the purposeful antibody response elicited following standard-of-care vaccination, together with evaluating the efficacy of under-development influenza vaccines in each animal fashions and medical trial settings. Nonetheless, utilizing the classical HAI method it’s not attainable to dissect the complexities of variable epitope recognition inside a polyclonal antibody response.
On this communication, we describe a simple aggressive HAI-based technique utilizing a mixture of influenza virus and recombinant hemagglutinin (HA) proteins to dissect the HAI purposeful exercise of HA-specific antibody populations in a single assay format. Significance: The hemagglutination inhibition (HAI) assay is a well-established and reproducible technique that quantifies purposeful antibody exercise towards influenza viruses and particularly the aptitude of an antibody formulation to inhibit the binding of HA to sialic acid.
Nonetheless, the HAI assay doesn’t present with full insights on the breadth and epitope recognition of the antibody formulation, particularly within the context of polyclonal sera the place a number of antibody specificities contribute to the general noticed purposeful exercise. On this report we introduce the usage of Y98F point-mutated recombinant HA (HAΔSA) proteins, which lack sialic acid binding exercise, within the context of the HAI assay as a imply to soak up out sure HA-directed (i.e., strain-specific or cross-reactive) antibody populations.
BORG5 Antibody |
|||
| 45862-100ul | SAB | 100ul | EUR 302.4 |
BORG5 Antibody |
|||
| 45862-50ul | SAB | 50ul | EUR 224.4 |
BORG1 antibody |
|||
| 70R-35308 | Fitzgerald | 100 ug | EUR 392.4 |
|
Description: Purified Rabbit polyclonal BORG1 antibody |
|||
BORG4 antibody |
|||
| 70R-35466 | Fitzgerald | 100 ug | EUR 392.4 |
|
Description: Purified Rabbit polyclonal BORG4 antibody |
|||
BORG5 Antibody |
|||
| ABD9356 | Lifescience Market | 100 ug | EUR 525.6 |
BORG1 Antibody |
|||
| ABD3908 | Lifescience Market | 100 ug | EUR 525.6 |
BORG2 Antibody |
|||
| ABD3909 | Lifescience Market | 100 ug | EUR 525.6 |
BORG4 Antibody |
|||
| ABD3910 | Lifescience Market | 100 ug | EUR 525.6 |
BORG1 Antibody |
|||
| 34556-100ul | SAB | 100ul | EUR 302.4 |
BORG1 Antibody |
|||
| 34556-50ul | SAB | 50ul | EUR 224.4 |
BORG4 Antibody |
|||
| 34558-100ul | SAB | 100ul | EUR 302.4 |
BORG4 Antibody |
|||
| 34558-50ul | SAB | 50ul | EUR 224.4 |
BORG5 Antibody |
|||
| DF9356 | Affbiotech | 200ul | EUR 420 |
BORG1 Antibody |
|||
| DF3908 | Affbiotech | 200ul | EUR 420 |
BORG2 Antibody |
|||
| DF3909 | Affbiotech | 200ul | EUR 420 |
BORG4 Antibody |
|||
| DF3910 | Affbiotech | 200ul | EUR 420 |
Binder of Rho GTPases 1 (BORG1) Antibody |
|||
| 20-abx014328 | Abbexa |
|
|
Binder of Rho GTPases 2 (BORG2) Antibody |
|||
| 20-abx014329 | Abbexa |
|
|
Binder of Rho GTPases 4 (BORG4) Antibody |
|||
| abx148629-100ug | Abbexa | 100 ug | EUR 526.8 |
Binder of Rho GTPases 5 (BORG5) Antibody |
|||
| 20-abx149128 | Abbexa |
|
|
BORG5 Polyclonal Antibody |
|||
| ABP57921-003ml | Abbkine | 0.03ml | EUR 189.6 |
|
Description: A polyclonal antibody for detection of BORG5 from Human. This BORG5 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human BORG5 protein |
|||
BORG5 Polyclonal Antibody |
|||
| ABP57921-01ml | Abbkine | 0.1ml | EUR 346.8 |
|
Description: A polyclonal antibody for detection of BORG5 from Human. This BORG5 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human BORG5 protein |
|||
BORG5 Polyclonal Antibody |
|||
| ABP57921-02ml | Abbkine | 0.2ml | EUR 496.8 |
|
Description: A polyclonal antibody for detection of BORG5 from Human. This BORG5 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human BORG5 protein |
|||
BORG5 Conjugated Antibody |
|||
| C45862 | SAB | 100ul | EUR 476.4 |
BORG1 Conjugated Antibody |
|||
| C34556 | SAB | 100ul | EUR 476.4 |
BORG4 Conjugated Antibody |
|||
| C34558 | SAB | 100ul | EUR 476.4 |
BORG5 Polyclonal Antibody |
|||
| ES9517-100ul | ELK Biotech | 100ul | EUR 334.8 |
|
Description: A Rabbit Polyclonal antibody against BORG5 from Human. This antibody is tested and validated for WB, ELISA, WB, ELISA |
|||
BORG5 Polyclonal Antibody |
|||
| ES9517-50ul | ELK Biotech | 50ul | EUR 248.4 |
|
Description: A Rabbit Polyclonal antibody against BORG5 from Human. This antibody is tested and validated for WB, ELISA, WB, ELISA |
|||
Anti-BORG3 Antibody |
|||
| A30601 | BosterBio | 100ul | EUR 476.4 |
|
Description: Rabbit Polyclonal BORG3 Antibody. Validated in WB and tested in Human, Mouse. |
|||
Anti-BORG3 Antibody |
|||
| A14184 | BosterBio | 100ul | EUR 476.4 |
|
Description: Rabbit Polyclonal BORG3 Antibody. Validated in WB and tested in Human, Mouse. |
|||
Anti-Dnmt3b Rabbit Monoclonal Antibody Rabbit Monoclonal Antibody |
|||
| M00319 | BosterBio | 100ug/vial | EUR 476.4 |
|
Description: Rabbit Monoclonal Dnmt3b Antibody Antibody. Validated in IF, ICC, WB and tested in Human, Mouse, Rat. |
|||
Rabbit Tpa Antibody |
|||
| abx023929-02mg | Abbexa | 0.2 mg | EUR 727.2 |
Rabbit IgG Antibody |
|||
| R20478-100UG | NSJ Bioreagents | 100ug | EUR 409 |
Rabbit Anti Borrelia Burgdorferi Polyclonal Antibody |
|||
| DPBT-66813RB | Creative Diagnostics | 1 ml | EUR 920.4 |
Rabbit VWCE antibody |
|||
| orb5385 | Biorbyt | 200ug | EUR 446 |
Rabbit Albumin Antibody |
|||
| 40150-05011 | AssayPro | 150 ug | EUR 260.4 |
Rabbit Anti Borrelia Burgdorferi Polyclonal Antibody,HRP |
|||
| DPBT-66812RB | Creative Diagnostics | 1 ml | EUR 1070.4 |
Rabbit Anti Borrelia Burgdorferi Polyclonal Antibody,FITC |
|||
| DPBT-66811RB | Creative Diagnostics | 1 ml | EUR 1008 |
Rabbit IgG Fc Antibody |
|||
| R20173-100UG | NSJ Bioreagents | 100ug | EUR 339.15 |
|
Description: This recombinant Rabbit IgG Fc antibody reacts to the Fc region of Rabbit IgG. No cross reactivity with human/mouse/rat IgG. |
|||
Rabbit IgG Fc Antibody |
|||
| R20173BTN-50UG | NSJ Bioreagents | 50ug | EUR 339.15 |
|
Description: This recombinant Rabbit IgG Fc antibody reacts to the Fc region of Rabbit IgG. No cross reactivity with human IgG, rat IgG, or mouse IgG. |
|||
Rabbit IgG Fc Antibody |
|||
| R20173SAF-250UG | NSJ Bioreagents | 250ug | EUR 832.15 |
|
Description: This recombinant Rabbit IgG Fc antibody reacts to the Fc region of Rabbit IgG. No cross reactivity with human/mouse/rat IgG. |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC470375-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF647 conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC470375-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF647 conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC550375-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF555 conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC550375-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF555 conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC400375-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF640R conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC400375-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF640R conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC430375-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF543 conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC430375-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF543 conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC810375-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF680R conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC810375-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF680R conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC610375-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF660R conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC610375-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF660R conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNUM0375-50 | Biotium | 50uL | EUR 474 |
|
Description: Primary antibody against p40(Rabbit PAb), 1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNCB0375-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p40(Rabbit PAb), Biotin conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNCB0375-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p40(Rabbit PAb), Biotin conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNCP0375-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against p40(Rabbit PAb), PerCP conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNCA0375-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against p40(Rabbit PAb), APC conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNCAP0375-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p40(Rabbit PAb), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNCAP0375-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p40(Rabbit PAb), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC940375-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF594 conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC940375-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF594 conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNCH0375-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p40(Rabbit PAb), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNCH0375-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p40(Rabbit PAb), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNUB0375-100 | Biotium | 100uL | EUR 250.8 |
|
Description: Primary antibody against p40(Rabbit PAb), Concentration: 0.2mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNUB0375-500 | Biotium | 500uL | EUR 549.6 |
|
Description: Primary antibody against p40(Rabbit PAb), Concentration: 0.2mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC040375-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF405S conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC040375-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF405S conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC050375-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF405M conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC050375-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF405M conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC700375-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF770 conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC700375-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF770 conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC880375-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF488A conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC880375-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF488A conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC800375-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF680 conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC800375-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF680 conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC680375-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF568 conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNC680375-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p40(Rabbit PAb), CF568 conjugate, Concentration: 0.1mg/mL |
|||
p40(Rabbit PAb) Antibody |
|||
| BNCR0375-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against p40(Rabbit PAb), RPE conjugate, Concentration: 0.1mg/mL |
|||
Rabbit IgG Fab Antibody |
|||
| R20172-100UG | NSJ Bioreagents | 100ug | EUR 339.15 |
|
Description: This recombinant Rabbit IgG Fab antibody reacts to the Fab region of Rabbit IgG. No cross reactivity with human/mouse/rat IgG. |
|||
Rabbit IgG Fab Antibody |
|||
| R20172BTN-50UG | NSJ Bioreagents | 50ug | EUR 339.15 |
|
Description: This recombinant Rabbit IgG Fab antibody reacts to the Fab region of Rabbit IgG. No cross reactivity with human IgG, rat IgG, or mouse IgG |
|||
Rabbit IgG Fab Antibody |
|||
| R20172SAF-250UG | NSJ Bioreagents | 250ug | EUR 832.15 |
|
Description: This recombinant Rabbit IgG Fab antibody reacts to the Fab region of Rabbit IgG. No cross reactivity with human/mouse/rat IgG. |
|||
Rabbit Anti FITC Antibody |
|||
| E61I01402 | EnoGene | 100ug | EUR 411.6 |
CD3e(Rabbit PAb) Antibody |
|||
| BNC470385-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD3e(Rabbit PAb), CF647 conjugate, Concentration: 0.1mg/mL |
|||
CD3e(Rabbit PAb) Antibody |
|||
| BNC470385-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD3e(Rabbit PAb), CF647 conjugate, Concentration: 0.1mg/mL |
|||
CD8a(Rabbit PAb) Antibody |
|||
| BNC470386-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD8a(Rabbit PAb), CF647 conjugate, Concentration: 0.1mg/mL |
|||
CD8a(Rabbit PAb) Antibody |
|||
| BNC470386-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD8a(Rabbit PAb), CF647 conjugate, Concentration: 0.1mg/mL |
|||
CD3e(Rabbit PAb) Antibody |
|||
| BNC550385-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD3e(Rabbit PAb), CF555 conjugate, Concentration: 0.1mg/mL |
|||
CD3e(Rabbit PAb) Antibody |
|||
| BNC550385-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD3e(Rabbit PAb), CF555 conjugate, Concentration: 0.1mg/mL |
|||
CD8a(Rabbit PAb) Antibody |
|||
| BNC550386-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD8a(Rabbit PAb), CF555 conjugate, Concentration: 0.1mg/mL |
|||
CD8a(Rabbit PAb) Antibody |
|||
| BNC550386-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD8a(Rabbit PAb), CF555 conjugate, Concentration: 0.1mg/mL |
|||
CD3e(Rabbit PAb) Antibody |
|||
| BNC400385-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD3e(Rabbit PAb), CF640R conjugate, Concentration: 0.1mg/mL |
|||
CD3e(Rabbit PAb) Antibody |
|||
| BNC400385-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD3e(Rabbit PAb), CF640R conjugate, Concentration: 0.1mg/mL |
|||
CD8a(Rabbit PAb) Antibody |
|||
| BNC400386-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD8a(Rabbit PAb), CF640R conjugate, Concentration: 0.1mg/mL |
|||
CD8a(Rabbit PAb) Antibody |
|||
| BNC400386-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD8a(Rabbit PAb), CF640R conjugate, Concentration: 0.1mg/mL |
|||
CD3e(Rabbit PAb) Antibody |
|||
| BNC430385-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD3e(Rabbit PAb), CF543 conjugate, Concentration: 0.1mg/mL |
|||
CD3e(Rabbit PAb) Antibody |
|||
| BNC430385-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD3e(Rabbit PAb), CF543 conjugate, Concentration: 0.1mg/mL |
|||
CD8a(Rabbit PAb) Antibody |
|||
| BNC430386-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD8a(Rabbit PAb), CF543 conjugate, Concentration: 0.1mg/mL |
|||
CD8a(Rabbit PAb) Antibody |
|||
| BNC430386-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD8a(Rabbit PAb), CF543 conjugate, Concentration: 0.1mg/mL |
|||
CD3e(Rabbit PAb) Antibody |
|||
| BNC810385-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD3e(Rabbit PAb), CF680R conjugate, Concentration: 0.1mg/mL |
|||
CD3e(Rabbit PAb) Antibody |
|||
| BNC810385-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD3e(Rabbit PAb), CF680R conjugate, Concentration: 0.1mg/mL |
|||
CD8a(Rabbit PAb) Antibody |
|||
| BNC810386-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD8a(Rabbit PAb), CF680R conjugate, Concentration: 0.1mg/mL |
|||
CD8a(Rabbit PAb) Antibody |
|||
| BNC810386-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD8a(Rabbit PAb), CF680R conjugate, Concentration: 0.1mg/mL |
|||
CD3e(Rabbit PAb) Antibody |
|||
| BNC610385-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD3e(Rabbit PAb), CF660R conjugate, Concentration: 0.1mg/mL |
|||
CD3e(Rabbit PAb) Antibody |
|||
| BNC610385-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD3e(Rabbit PAb), CF660R conjugate, Concentration: 0.1mg/mL |
|||
CD8a(Rabbit PAb) Antibody |
|||
| BNC610386-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD8a(Rabbit PAb), CF660R conjugate, Concentration: 0.1mg/mL |
|||
CD8a(Rabbit PAb) Antibody |
|||
| BNC610386-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD8a(Rabbit PAb), CF660R conjugate, Concentration: 0.1mg/mL |
|||
CD3e(Rabbit PAb) Antibody |
|||
| BNUM0385-50 | Biotium | 50uL | EUR 474 |
|
Description: Primary antibody against CD3e(Rabbit PAb), 1mg/mL |
|||
CD8a(Rabbit PAb) Antibody |
|||
| BNUM0386-50 | Biotium | 50uL | EUR 474 |
|
Description: Primary antibody against CD8a(Rabbit PAb), 1mg/mL |
|||
CD3e(Rabbit PAb) Antibody |
|||
| BNCB0385-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD3e(Rabbit PAb), Biotin conjugate, Concentration: 0.1mg/mL |
|||
CD3e(Rabbit PAb) Antibody |
|||
| BNCB0385-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD3e(Rabbit PAb), Biotin conjugate, Concentration: 0.1mg/mL |
|||
This modification to the classical HAI assay, known as the aggressive HAI assay, represents a brand new instrument to dissect the magnitude and breadth of polyclonal antibodies elicited by way of vaccination or pure an infection.
